Rising Prevalence of Mental Depression & Anxiety Major Drivers Propelling Demand In Psychedelic Drugs Market – PRNewswire

Rising prevalence of depression and anxiety are major drivers in the increased demand for psychedelic drugs

CONTEXT:  This article reviews the increasing demand for psychedelic drugs in the treatment of depression and anxiety overall, but contains the news that Compass Pathways plc has recently signed a memorandum of understanding (MoU) with UK mental health institutions to build on their commitment to improving innovation in mental health.  The MoU is with South London and Maudsley NHS Trust and the Institute of Psychiatry at King’s College London.  The research will include work on Compass’ psilocybin therapy, but it is also intended to include training therapists in psychedelic therapy, generating real-world evidence, building state-of-the-art research facilities and modelling the “mental health care clinic of the future”. READ TIME:  2 mins 1. “COMPASS Pathways plc (NASDAQ: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has recently signed a Memorandum of Understanding (MoU) with South London and Maudsley NHS Foundation Trust (SLaM) and the Institute of Psychiatry, Psychology and Neuroscience (IoPPN) at King’s College London, aimed at advancing psychedelic research and developing ambitious new models of care for mental health in the UK.”  2. “Active companies in the market this week include Optimi Health Corp. (OTCQB: OPTHF) (CSE: OPTI), MindMed (NASDAQ: MNMD), COMPASS Pathways plc (NASDAQ: CMPS), Atai Life Sciences B.V. (NASDAQ: ATAI), Cybin Inc. (OTCQB: CLXPF) (NEO: CYBN).”  3. “Read this full release and more news for Optimi Health Corp. at: recent developments in the biotech industry include:. MindMed (NASDAQ: MNMD), a leading psychedelic-inspired medicine company recently announced that effective Friday, June 25th, 2021, MindMed has been added to the FTSE Russell 3000®index which measures the performance of the largest 3,000 US companies.”  4. “Atai Life Sciences B.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, recently announced the pricing of its upsized initial public offering in the United States of 15,000,000 common shares at a price to the public of $15.00 per share.”  5. “Greenbrook’s affiliated physicians have treated over 17,000 patients suffering from Major Depressive Disorder and other mental health disorders in the United States, while Cybin is a leader in the research and development of novel compounds and delivery mechanisms and is building the foundation of what it believes will become the next generation of commercially viable psychedelic therapeutics for the treatment of mental health disorders, including depression.”  Source URL: https://www.prnewswire.com/news-releases/rising-prevalence-of-mental-depression–anxiety-major-drivers-propelling-demand-in-psychedelic-drugs-market-301326593.html